Patient complexity and risk factor control among multimorbid patients with type 2 diabetes: Results from the R2D2C2 study

Medical Care

Volumn 51, Issue 2, 2013, Pages 180-185

  Malik, Shaista ^a   Billimek, John ^a   Greenfield, Sheldon ^a   Sorkin, Dara H ^a   Ngo Metzger, Quyen ^b   Kaplan, Sherrie H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HEALTH RESOURCES AND SERVICES ADMINISTRATION   (United States)

Author keywords

cardiovascular disease; comorbidity; diabetes; patient complexity; risk factors

Indexed keywords

INSULIN;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

CHI-SQUARE DISTRIBUTION; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 84872867448     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e318273119b     Document Type: Article

References (34)

1. Greenfield S, Billimek J, Pellegrini F, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med. 2009;151:854-860.
2. Kerr EA, Heisler M, Krein SL, et al. Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients' treatment priorities and self-management? J Gen Intern Med. 2007;22:1635-1640.
3. Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;17:814-822.
4. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
5. Morris AB, Li J, Kroenke K, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy. 2006;26:483-492.
6. Romanelli J, Fauerbach JA, Bush DE, et al. The significance of depression in older patients after myocardial infarction. J Am Geriatr Soc. 2002;50:817-822.
7. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med. 2007;120:26-32.
8. Kaplan SH, Billimek J, Sorkin DH, et al. Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects. Med Care. 2010;48:S9-S16.
9. Sorkin DH, Ngo-Metzger Q, Billimek J, et al. Underdiagnosed and undertreated depression among racially/ethnically diverse patients with type 2 diabetes. Diabetes Care. 2011;34:598-600.
10. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
11. Wang H, Steffen LM, Jacobs DR, et al. Trends in cardiovascular risk factor levels in the Minnesota Heart Survey (1980-2002) as compared with the National Health and Nutrition Examination Survey (1976-2002): a partial explanation for Minnesota's low cardiovascular disease mortality? Am J Epidemiol. 2011;173:526-538.
12. Greenfield S, Sullivan L, Dukes KA, et al. Development and testing of a new measure of case mix for use in office practice. Med Care. 1995;33(suppl):AS47-AS55.
13. Litwin M, Greenfield S, Elkin E, et al. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007;109:1777-1783.
14. Stier DM, Greenfield S, Lubeck DP, et al. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology. 1999;54:424-429.
15. Ware JE Jr, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33:AS264-AS279.
16. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
17. Greenfield S, Kaplan SH, Silliman RA, et al. The uses of outcomes research for medical effectiveness, quality of care and reimbursement in type II diabetes. Diabetes Care. 1994;17(suppl 1):32-39.
18. Silliman RA, Bhatti S, Knan A, et al. The care of older persons with diabetes mellitus: families and primary care physicians. J Am Geriatr Soc. 1996;44:1314-1321.
19. Kaplan SH, Dukes KA, Sullivan LM, et al. Is passivity a risk factor for poor health outcomes? J Gen Int Med. 1996;11(suppl 1):76.
20. Sherbourne CD, Hays RD, Ordway L, et al. Antecedents of adherence to medical recommendations: results from the Medical Outcomes Study. J Behav Med. 1992;15:447-468.
21. Grant RW, O'Leary KM, Weilburg JB, et al. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004;164:2343-2348.
22. Lamb DA, Eurich DT, McAlister FA, et al. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003. Circ Cardiovasc Qual Outcomes. 2009;2:228-235.
23. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
24. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836-1841.
25. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther. 2008; 30:2167-2179.
26. Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27:2800-2805.
27. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671-679.
28. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
29. Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc (2003). 2011;51: 90-94.
30. Dobbels F, Berben L, De Geest S, et al. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation. 2010;90:205-219.
31. Voils CI, Hoyle RH, Thorpe CT, et al. Improving the measurement of selfreported medication nonadherence. J Clin Epidemiol. 2011;64:250-254.
32. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-1462.
33. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147-1152.
34. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997; 10(pt 1):697-704.